Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Meeting on the Mesa 2021 and Meeting On The Mesa 2021 View overview page

1:16
Overcoming immunogenicity of gene therapies
Timothy Miller • 18 Nov 2021
0:59
RESKUE: AAV-based gene therapy for Krabbe disease
Timothy Miller • 18 Nov 2021
1:58
Increasing manufacturing capabilities for gene therapies
Timothy Miller • 18 Nov 2021
2:07
Treating Krabbe disease with AAV-based gene therapies
Timothy Miller • 18 Nov 2021
2:20
Remaining barriers in commercializing advanced therapies
Pascal Touchon • 22 Oct 2021
3:59
ATA3219, ATA3271 & ATA188: T-Cell immunotherapy products in development
Pascal Touchon • 22 Oct 2021
1:49
Next steps for procine-derived bioengineered organs
Jeff Ross • 28 Oct 2021
1:08
Can manufacturing bioengineered organs be scaled up?
Jeff Ross • 28 Oct 2021
3:58
Remaining challenges in developing cell therapies for cancer
Pascal Touchon • 22 Oct 2021
3:09
The current landscape of allogeneic CAR T-cell therapies
Pascal Touchon • 22 Oct 2021
2:03
The Tapestri Platform: a single-cell multi-omics system
Yan Zhang • 21 Oct 2021
7:04
Applications of single-cell multi-omics analysis
Yan Zhang • 21 Oct 2021
1:50
Utilizing single-cell multi-omics throughout the product pipeline
Yan Zhang • 21 Nov 2021
1:27
The future of gene therapies for the eye
Sue Washer • 22 Oct 2021
1:34
Impact of COVID-19 on the advanced therapies sector
Christian Schneider • 29 Oct 2021
2:29
Manufacturing challenges in the advanced therapies sector
Sue Washer • 22 Oct 2021
The content of VJRegenMed is intended for healthcare professionals